evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

64 questions · 64 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 8 · 12.5%GRADE not reported 0 · 0%Very low 26 · 40.6%Low 18 · 28.1%Moderate 12 · 18.8%High 0 · 0%

Low molecular weight heparin vs vitamin K antagonist (VKA)

Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).

1 finding from 1 review

Intervention not reported

Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days

The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).

1 finding from 1 review

Intervention not reported

HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days

The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).

1 finding from 1 review

Intervention not reported

HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days

The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).

1 finding from 1 review